Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Bicara Therapeutics

Tracked across 14 events · 152 articles · First seen May 05, 2026 · Last active Sep 22, 2026

Sentiment
24
Attention
6
Events
14
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Business
Impact: Bicara Therapeutics secured $180 million in financing to advance its lead drug candidate, deupirfenidone, for idiopathic pulmonary fibrosis, enabling the initiation of a crucial Phase 3 trial.
Jul 02, 2026 · 6 articles
2 80
Business
Impact: Bicara Therapeutics is the central entity, successfully closing an oversubscribed Series A financing round of nearly $30 million. This funding will accelerate its AI-driven drug discovery platform and pipeline development, enhancing its competitive position and growth prospects.
Jul 20, 2026 · 6 articles
2 25
Business
Impact: Mesenkia is a key party, providing its KITAIbodies platform and antibody targeting HVEM. The collaboration validates its technology and provides resources to advance its glioblastoma program.
Aug 19, 2026 · 6 articles
1 25
Tech
Bicara Therapeutics AB, a privately held Swedish precision medicine company, announced on September 22, 2026 the initiation of IND-enabling studies for BEA-17, its wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST,…
Impact: Bicara Therapeutics is the central actor, initiating IND-enabling studies for BEA-17 and advancing its wholly owned glioblastoma programme toward first-in-human trials. The milestone strengthens its pipeline narrative and supports future value creation and shareholder expectations, though it remains a privately held company with no near-term revenue.
Sep 22, 2026 · 6 articles
3 60
Business
Impact: Kaveri receives exclusive rights to two promising oncology programs and seed funding, positioning it to advance clinical trials and raise additional capital.
Jul 21, 2026 · 7 articles
6 60
Business
Impact: Bicara Therapeutics, a Nasdaq-listed firm incubated by Biocon, is led by Claire Mazumdar and has seen its market capitalization exceed $1.6 billion under her leadership.
May 05, 2026 · 40 articles
2 0
Regulatory
Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023…
Impact: Keenova's Testim is used off-label by women, but the company did not respond to inquiries.
Sep 15, 2026 · 6 articles
2 0
Business
Jul 14, 2026 · 6 articles
1 -5
Regulatory
Impact: Acquirer in the Rallybio merger; subject to investigation.
Jul 20, 2026 · 20 articles
0 0
Business
Impact: Bicara Therapeutics is the current employer of Vicky Papoutsis, but the event does not directly affect the company.
Jul 30, 2026 · 6 articles
2 10
Business
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its…
Impact: Cited as a peer that debuted after raising $350 million in an upsized IPO, illustrating the reopened biotech listing window.
Sep 21, 2026 · 6 articles
3 0
Business
Impact: Bicara Therapeutics is mentioned as a co-development partner for Insilico's CNS program, but is not directly involved in this event.
Jul 13, 2026 · 6 articles
4 0
Business
Impact: Bicara Therapeutics was acquired by Eli Lilly earlier in 2026, a genetic-medicine biotechnology company.
Jul 16, 2026 · 25 articles
1 0
Business
Impact: Bicara Therapeutics is mentioned as a company where Brosgart previously held a board position and where she worked with CEO Sapirstein; no direct impact.
Aug 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Bicara Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.